

## Company Statement Regarding Coronavirus Disease 2019 (COVID-19)

---

Bionique Testing Laboratories (BTL) is vigilantly monitoring the international outbreak of coronavirus disease 2019 (COVID-19) and staying abreast of guidance provided by the Centers for Disease Control and prevention (CDC), NYS Department of Health (NYSDOH), The U.S. Department of Labor's Occupational Safety and Health Administration (OSHA) and all other applicable authorities.

BTL is a GMP compliant FDA registered facility that provides mycoplasma testing services for the life science industry and has been deemed an essential business.

BTL has a business continuity plan that is designed to respond to a wide variety of events. The plan specifically defines organizational and decision-making authorities in the event for any occurrence that could lead to disruption of business activities. Each department has evaluated which employees will be able to work remotely and which employees are critical to support ongoing daily operations. In addition, we have implemented strict employee travel and visitor policies for the duration of the current pandemic.

BTL has carried out a supply chain risk assessment and has formulated contingency plans to mitigate risks to any goods identified as vulnerable to coronavirus-related disruption. BTL has been in communication with Approved Criticality Suppliers to ensure continued supply of high criticality supplies.

BTL's Human Resources Department (HR) has advised all staff of precautionary measures to undertake based on the guidance of the Centers for Disease Control and prevention (CDC), NYS Department of Health, and The United States Department of Labor OSHA.

BTL recognizes the unusual circumstances associated with the coronavirus pandemic and is closely monitoring this rapidly changing situation. We will continue to provide updates during this critical period through proactive notification to our customers and also post updated information on our website.